Godshalk Welsh Capital Management’s AbbVie ABBV Stock Holding History

Godshalk Welsh Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.13M	Sell	5,181 -100	-2%	-$22.2K	0.65%	58
2025 Q4	$1.21M	Sell	5,281 -25	-0.5%	-$5.7K	0.69%	48
2025 Q3	$1.23M	Hold	5,306	–	–	0.7%	44
2025 Q2	$985K	Sell	5,306 -350	-6%	-$65K	0.61%	52
2025 Q1	$1.19M	Hold	5,656	–	–	0.78%	46
2024 Q4	$1.01M	Sell	5,656 -25	-0.4%	-$4.6K	0.65%	52
2024 Q3	$1.12M	Hold	5,681	–	–	0.71%	45
2024 Q2	$974K	Hold	5,681	–	–	0.65%	50
2024 Q1	$1.03M	Sell	5,681 -25	-0.4%	-$4.31K	0.7%	48
2023 Q4	$884K	Sell	5,706 -800	-12%	-$117K	0.64%	55
2023 Q3	$970K	Sell	6,506 -775	-11%	-$114K	0.73%	48
2023 Q2	$981K	Sell	7,281 -75	-1%	-$11K	0.68%	50
2023 Q1	$1.17M	Sell	7,356 -50	-0.7%	-$7.64K	0.83%	44
2022 Q4	$1.2M	Sell	7,406 -244	-3%	-$37.4K	0.87%	43
2022 Q3	$1.03M	Buy	7,650 +187	+3%	+$26.8K	0.76%	48
2022 Q2	$1.14M	Hold	7,463	–	–	0.82%	46
2022 Q1	$1.21M	Sell	7,463 -168	-2%	-$24.4K	0.74%	48
2021 Q4	$1.03M	Hold	7,631	–	–	0.59%	56
2021 Q3	$823K	Hold	7,631	–	–	0.51%	63
2021 Q2	$897K	Hold	7,631	–	–	0.56%	58
2021 Q1	$826K	Sell	7,631 -50	-0.7%	-$5.35K	0.58%	58
2020 Q4	$823K	Buy	7,681 +150	+2%	+$14.4K	0.61%	58
2020 Q3	$660K	Buy	7,531 +100	+1%	+$9.41K	0.56%	60
2020 Q2	$730K	Sell	7,431 -77	-1%	-$6.78K	0.68%	57
2020 Q1	$572K	Hold	7,508	–	–	0.62%	63
2019 Q4	$665K	Hold	7,508	–	–	0.55%	67
2019 Q3	$569K	Sell	7,508 -150	-2%	-$10.3K	0.5%	72
2019 Q2	$557K	Hold	7,658	–	–	0.51%	71
2019 Q1	$617K	Hold	7,658	–	–	0.59%	63
2018 Q4	$706K	Sell	7,658 -50	-0.6%	-$4.4K	0.79%	50
2018 Q3	$729K	Hold	7,708	–	–	0.71%	55
2018 Q2	$714K	Hold	7,708	–	–	0.75%	53
2018 Q1	$730K	Hold	7,708	–	–	0.79%	51
2017 Q4	$745K	Sell	7,708 -600	-7%	-$56.5K	0.75%	54
2017 Q3	$738K	Sell	8,308 -800	-9%	-$60.9K	0.74%	58
2017 Q2	$660K	Sell	9,108 -450	-5%	-$30.3K	0.66%	61
2017 Q1	$623K	Sell	9,558 -800	-8%	-$50.3K	0.61%	65
2016 Q4	$649K	Sell	10,358 -500	-5%	-$30.5K	0.66%	61
2016 Q3	$685K	Hold	10,858	–	–	0.71%	55
2016 Q2	$685K	Sell	10,858 -300	-3%	-$18.3K	0.72%	54
2016 Q1	$637K	Sell	11,158 -150	-1%	-$8.36K	0.66%	58
2015 Q4	$670K	Hold	11,308	–	–	0.7%	51
2015 Q3	$615K	Hold	11,308	–	–	0.67%	56
2015 Q2	$760K	Sell	11,308 -617	-5%	-$40.3K	0.77%	49
2015 Q1	$698K	Sell	11,925 -300	-2%	-$18.1K	0.71%	56
2014 Q4	$800K	Buy	+12,225	New	+$771K	0.73%	49

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Godshalk Welsh Capital Management's ABBV Position: Q1 2026 in Review

Godshalk Welsh Capital Management reduced its AbbVie (ABBV) stake by 1.9% in Q1 2026, selling an estimated $22.2K and leaving 5,181 shares worth $1.13M. The position accounts for 0.65% of the portfolio, ranked #58.

Godshalk Welsh Capital Management first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.23M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Godshalk Welsh Capital Management held 5,181 shares of AbbVie worth $1.13M as of Q1 2026.
Godshalk Welsh Capital Management sold 100 AbbVie shares in Q1 2026, an estimated $22.2K.
AbbVie made up 0.65% of Godshalk Welsh Capital Management's portfolio in Q1 2026, its #58 holding.
Godshalk Welsh Capital Management first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
Godshalk Welsh Capital Management's AbbVie position peaked at $1.23M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Godshalk Welsh Capital Management's 13F filing for Q1 2026, filed 13 May 2026.